WINNIPEG, MB–(Marketwired – October 27, 2016) – 3D Signatures Inc. (TSX VENTURE: DXD) (the “Company” or “3DS”) is pleased to introduce the following internationally renowned senior biotech executives as members of the Company’s Business Advisory Board.

Jonathan Goodman, Director & CEO, Knight Therapeutics Inc.

Mr. Goodman is the founder and CEO of Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “Knight Therapeutics”), a specialty pharmaceutical company headquartered in Quebec, Canada. Knight was established by Mr. Goodman in 2014, and has a current market cap of approximately $1.2 billion. Prior to Knight, Mr. Goodman was a co-founder, President and CEO of Paladin Labs Inc. (“Paladin Labs”) which was acquired by Endo International plc (TSX: ENL) in February 2014 for $3.2 billion. Mr. Goodman was formerly a consultant with Bain & Company and also worked in brand management for Procter & Gamble. Mr. Goodman holds a B.A. from McGill University (Great Distinction) and the London School of Economics (1st Class Honours). Additionally, he holds an LL.B. and an M.B.A. from McGill University.

Bringing proven international success with Paladin Labs and Knight Therapeutics, 3DS will greatly benefit from Mr. Goodman’s entrepreneurial experience and global networks, both in the pharmaceutical industry and in healthcare capital markets. Knight Therapeutics is a strategic investor in 3DS.

Dr. Heiner Dreismann, Past President and CEO, Roche Molecular Systems

Dr. Dreismann is a seasoned executive with more than 24 years of experience in the healthcare industry, and is regarded as a pioneer in the early adoption of the polymerase chain reaction (PCR) technique, one of the most ubiquitous technologies in molecular biology and genetics research today. He had a successful career at the Roche Group from 1985 to 2006 where he held several senior positions, including President and CEO, Roche Molecular Systems, Head of Global Business Development, Roche Diagnostics, and Member of Roche’s Global Diagnostic Executive Committee. At the time of his departure, Dr. Dreismann had grown Roche Molecular Systems to approximately $1.2 billion USD in annual revenue. He currently serves on the boards of several public and private health care companies. Dr. Dreismann earned a MSc degree in biology and his Ph.D in microbiology/molecular biology (summa cum laude) from Westfaelische Wilhelms University (The University of Munster) in Germany.

Dr. Dreismann brings proven strategic vision and world-class diagnostics expertise to 3DS. The Company expects to benefit greatly from his substantial commercial networks and unparalleled global perspective on the medical diagnostics market.

John Lindsay, Founder, SciPartners

Mr. Lindsay began his career at Millipore Corporation, Merck KGaA, and quickly advanced to become the youngest Vice President in the history of the company. He was promoted to Executive Vice President of several divisions, including the Analytical Group and Milligen Biosearch Divisions. In 2000, he founded SciPartners, with the objective of building a platform for development of early stage European and North American firms. His focus is the life sciences market, and over the past 14 years he has successfully built up sales and marketing that led to rapid growth and increased revenues for many companies, and the acquisition of ProXeon by ThermoFisher as well as the acquisition of Halo Genomics by Agilent.

Mr. Lindsay’s history of repeated commercial success, working with major healthcare companies, as well as small and emerging life sciences companies, will greatly aid 3DS as it endeavors to become a leading diagnostic and prognostic company for cancer and Alzheimer’s disease.

Comments from 3DS Chairman

“In a very short time, we have built an exceptional Business Advisory Board,” said John Swift, Chairman, 3DS. “This speaks to the strength of our technology and to the magnitude of our business opportunity. As the Company advances its first-in-class minimally invasive tests for major diseases such as prostate cancer and Alzheimer’s disease, independent guidance from the Business Advisory Board will be of tremendous assistance in making the right decisions at the right time.”

3DS Opens Toronto Stock Exchange

To celebrate the recent September 13, 2016 listing on TSX Venture Exchange (TSXV), members of 3DS’ senior management and directors will open trading at Toronto Stock Exchange (TSX) on Wednesday, November 2 at 9:30 a.m. EDT.

About 3DS

3DS (TSX VENTURE: DXD) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis chromosomal signatures. The technology is well developed and supported by 16 clinical studies on over 1,500 patients on 13 different cancers and Alzheimer’s disease. Depending on the desired application, the technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company’s new website at http://www.3dsignatures.com.

Forward-Looking Information

This news release includes forward-looking statements that are subject to risks and uncertainties. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. All statements within, other than statements of historical fact, are to be considered forward looking. In particular, the Company’s statements that it expects to benefit greatly from its association with the individuals named in this news release is forward-looking information. Although 3DS believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Risk factors that could cause actual results or outcomes to differ materially from the results expressed or implied by forward-looking information include, among other things: market demand; technological changes that could impact the Company’s existing products or the Company’s ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; the ability to manage operating expenses, which may adversely affect the Company’s financial condition; the Company’s ability to successfully maintain and enforce its intellectual property rights and defend third-party claims of infringement of their intellectual property rights; adverse results or unexpected delays in clinical trials; changes in laws, general economic and business conditions; and changes in the regulatory regime. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:
Hugh Rogers
VP Corporate Finance
604-250-6162
[email protected]